Related Experiment Video
Updated: Aug 10, 2025

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
Published on: August 1, 2018
Correlation between the Warburg effect and progression of triple-negative breast cancer
Shaojun Liu1, Yuxuan Li1, Meng Yuan1
1Department of Oncology, Suzhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Suzhou, China.
Abstract:
Triple-negative breast cancer (TNBC) is ineligible for hormonal therapy and Her-2-targeted therapy due to the negative expression of the estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2. Although targeted therapy and immunotherapy have been shown to attenuate the aggressiveness of TNBC partially, few patients have benefited from them. The conventional treatment for TNBC remains chemotherapy. Chemoresistance, however, impedes therapeutic progress over time, and chemotherapy toxicity increases the burden of cancer on patients. Therefore, introducing more advantageous TNBC treatment options is a necessity. Metabolic reprogramming centered on glucose metabolism is considered a hallmark of tumors. It is described as tumor cells tend to convert glucose to lactate even under normoxic conditions, a phenomenon known as the Warburg effect. Similar to Darwinian evolution, its emergence is attributed to the selective pressures formed by the hypoxic microenvironment of pre-malignant lesions. Of note, the Warburg effect does not disappear with changes in the microenvironment after the formation of malignant tumor phenotypes. Instead, it forms a constitutive expression mediated by mutations or epigenetic modifications, providing a robust selective survival advantage for primary and metastatic lesions. Expanding evidence has demonstrated that the Warburg effect mediates multiple invasive behaviors in TNBC, including proliferation, metastasis, recurrence, immune escape, and multidrug resistance. Moreover, the Warburg effect-targeted therapy has been testified to be feasible in inhibiting TNBC progression. However, not all TNBCs are sensitive to glycolysis inhibitors because TNBC cells flexibly switch their metabolic patterns to cope with different survival pressures, namely metabolic plasticity. Between the Warburg effect-targeted medicines and the actual curative effect, metabolic plasticity creates a divide that must be continuously researched and bridged.
Insights
Triple-negative breast cancer (TNBC) cells exhibit the Warburg effect, fueling their aggressive growth and resistance to chemotherapy. Targeting this metabolic shift shows promise, but metabolic plasticity in TNBC requires further research for effective treatments.
Area of Science:
- Oncology
- Cancer Metabolism
- Molecular Biology
Background:
- Triple-negative breast cancer (TNBC) lacks targeted therapies, making chemotherapy the primary treatment.
- Chemoresistance and toxicity limit current TNBC treatment efficacy.
- Metabolic reprogramming, particularly the Warburg effect, is a hallmark of cancer, promoting tumor aggressiveness.
Purpose of the Study:
- To explore the role of the Warburg effect in TNBC progression.
- To investigate the potential of targeting the Warburg effect for TNBC treatment.
- To understand the impact of metabolic plasticity on therapeutic outcomes in TNBC.
Main Methods:
- Review of existing literature on TNBC metabolism and therapeutic strategies.
- Analysis of the Warburg effect's contribution to TNBC hallmarks like proliferation and metastasis.
- Examination of metabolic plasticity as a mechanism for resistance to glycolysis inhibitors.
Main Results:
- The Warburg effect is implicated in TNBC proliferation, metastasis, recurrence, immune escape, and multidrug resistance.
- Targeting the Warburg effect demonstrates potential in inhibiting TNBC progression.
- TNBC cells exhibit metabolic plasticity, allowing them to adapt to different pressures and evade targeted therapies.
Conclusions:
- The Warburg effect is a critical driver of TNBC aggressiveness and therapeutic resistance.
- Targeting metabolic reprogramming offers a potential therapeutic avenue for TNBC.
- Metabolic plasticity presents a significant challenge that must be addressed to bridge the gap between Warburg effect-targeted therapies and clinical efficacy in TNBC.
Related Concept Videos
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

